MET and hepatocellular carcinoma: It was recently shown that c-Met inhibition by tivantinib/capmatinib reduces GSK3B-mediated PDL-1 degradation, resulting in increased PDL-1 expression and inactivation of co-cultured T cells in the HCC cell line, as well as reduced anti-tumor activity of T cells in mouse models [42].